Filing Details

Accession Number:
0000899243-16-029181
Form Type:
4
Zero Holdings:
No
Publication Time:
2016-09-16 20:00:46
Reporting Period:
2016-09-15
Filing Date:
2016-09-16
Accepted Time:
2016-09-16 20:00:46
SEC Url:
Form 4 Filing
Issuer
Cik Name Symbol Sector (SIC) IRS No
1285819 Omeros Corp OMER Pharmaceutical Preparations (2834) 911663741
Insiders
Cik Name Reported Address Insider Title Director Officer Large Shareholder Other
1472163 S. Marcia Kelbon 201 Elliott Avenue West
Seattle WA 98119
Vp Patent And General Counsel No Yes No No
Reported Non-Derivative Transactions
Sec. Name Acquisiton - Disposition Date Amount Price Remaning Holdings Equity Swap Involved Form Type Code Nature of Ownership Explanation
Common Stock Acquisiton 2016-09-15 16,000 $0.98 179,597 No 4 M Direct
Common Stock Disposition 2016-09-15 16,000 $10.91 163,597 No 4 S Direct
Equity Swap Involved Form Type Code Nature of Ownership Explanation
No 4 M Direct
No 4 S Direct
Reported Derivative Transactions
Sec. Name Sec. Type Acquisiton - Disposition Date Amount Price Amount - 2 Price - 2
Common Stock Stock Option (Right to Buy) Disposition 2016-09-15 16,000 $0.00 16,000 $0.98
Remaning Holdings Exercise Date Expiration Date Equity Swap Involved Transaction Form Type Transaction Code Nature of Ownership
0 2016-12-11 No 4 M Direct
Footnotes
  1. Open market sale pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on June 3, 2014, and amended on May 13, 2016, which provided for the exercise and sale of options to purchase 175,000 shares of common stock that expire on December 11, 2016. The May 13, 2016 amendment to Ms. Kelbon's trading plan provided for the future exercise and sale of certain other series of the issuer's stock options. Under the plan, the options expiring on December 11, 2016 would be exercised and sold at fixed sale periods, price and numbers set at the time the plan was adopted in 2014 over a one-year period beginning in November 2015, with sale periods commencing approximately monthly and with approximately 15,900 such options to be exercised and sold in each sale period. This sale was the last scheduled sale of options expiring in 2016 under the plan. Consistent with applicable trading rules, Ms. Kelbon has had no further control over the terms or timing of sales under the plan.
  2. (Continued from Footnote 1) A portion of the proceeds from the exercise of the options expiring on December 11, 2016 are being used to fund Ms. Kelbon's exercise of other series of the issuer's stock options and retention of the underlying shares, and may also be used to fund the payment of taxes incurred by the exercise of such options.
  3. This transaction was executed in multiple trades at prices ranging from $10.69 to $11.08; the price reported above reflects the weighted average sales price. The reporting person hereby undertakes to provide full information regarding the number of shares and prices at which the transactions referenced in this footnote were effected upon request to the SEC staff, the issuer, or a security holder of the issuer.
  4. The option vested and became exercisable in 48 equal monthly installments. The first installment became exercisable on November 1, 2005 and subsequent installments became exercisable on each monthly anniversary thereafter.